In poorly immunogenic (primary ICI resistant) MOC2 tumor-bearing mice (Figure 1F) the virus treated groups gained significantly better responses, when looking at 30 day tumor growth curves in comparison to mock (p<0.05) and anti-PD-L1 monotherapy (p<0.01). Here, CD274 is linked to neoplasm.